Sana is Incorporating the Tested Immune Evasion Technology to Develop SC451, a HIP-modified, Stem Cell-Derived Therapy as a One-Time Treatment for Patients with Type 1 Diabetes, with a Goal of Normal ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Sana's first-in-human study shows HIP technology allows islet cells to avoid immune rejection and produce insulin without immunosuppression. Reliance on initial results: The press release heavily ...

MAIA Biotechnology, Inc. ((MAIA)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

PDS Biotechnology is hosting a virtual key opinion leader event featuring notable experts in the field, which could enhance the company’s credibility and visibility in the oncological community. The ...

On Tuesday, Sana Biotechnology Inc (NASDAQ:SANA) released the initial results from a first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s ...

In a new study published in GEN’s sister peer-review journal, GEN Biotechnology, titled, “Exploring Structure-Function Relationships in Engineered Receptor Performance Using Computational Structure ...

New study explores how fish by-products could drive Portugal’s blue biotech sector. A B2E CoLAB-led project will examine how ...

ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the ...

SAN FRANCISCO, March 23, 2026 (GLOBE NEWSWIRE)-- Siren Biotechnology today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application ...

You will have a wide range of opportunities for career preparation directly related to your field of study, all of which provide hands-on experiences that turn knowledge into know-how.

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results ...